Literature DB >> 34373613

Semaglutide and the risk of diabetic retinopathy-current perspective.

Ashish Sharma1, Nikulaa Parachuri2, Nilesh Kumar2,3, Bharat Saboo4, Hridaya Nath Tripathi5, Baruch D Kuppermann6, Francesco Bandello7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34373613      PMCID： PMC8727607          DOI： 10.1038/s41433-021-01741-5

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  9 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

Authors:  Vanita R Aroda; Stephen C Bain; Bertrand Cariou; Milivoj Piletič; Ludger Rose; Mads Axelsen; Everton Rowe; J Hans DeVries
Journal:  Lancet Diabetes Endocrinol       Date:  2017-03-23       Impact factor: 32.069

3.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Mansoor Husain; Andreas L Birkenfeld; Morten Donsmark; Kathleen Dungan; Freddy G Eliaschewitz; Denise R Franco; Ole K Jeppesen; Ildiko Lingvay; Ofri Mosenzon; Sue D Pedersen; Cees J Tack; Mette Thomsen; Tina Vilsbøll; Mark L Warren; Stephen C Bain
Journal:  N Engl J Med       Date:  2019-06-11       Impact factor: 91.245

4.  Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

Authors:  Bo Ahrén; Luis Masmiquel; Harish Kumar; Mehmet Sargin; Julie Derving Karsbøl; Sanja Hald Jacobsen; Francis Chow
Journal:  Lancet Diabetes Endocrinol       Date:  2017-04-03       Impact factor: 32.069

5.  Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Authors:  Christopher Sorli; Shin-Ichi Harashima; George M Tsoukas; Jeffrey Unger; Julie Derving Karsbøl; Thomas Hansen; Stephen C Bain
Journal:  Lancet Diabetes Endocrinol       Date:  2017-01-17       Impact factor: 32.069

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Authors:  Andrew J Ahmann; Matthew Capehorn; Guillaume Charpentier; Francesco Dotta; Elena Henkel; Ildiko Lingvay; Anders G Holst; Miriam P Annett; Vanita R Aroda
Journal:  Diabetes Care       Date:  2017-12-15       Impact factor: 19.112

9.  Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

Authors:  Helena W Rodbard; Ildiko Lingvay; John Reed; Raymond de la Rosa; Ludger Rose; Danny Sugimoto; Eiichi Araki; Pei-Ling Chu; Nelun Wijayasinghe; Paul Norwood
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 5.958
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.